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and T.E. Starzl 
WE have reponed that a short delayed course of intramuscular FK 506 can induce a donor strain-
specific immunologK unresponsiveness to cardiac allograft 
in rats. 1 Further studies have been performed to determine 
if this agent can induce graft acceptance after canine renal 
(KT) or hepatic (OL T) allotransplantation. Preliminary 
descriptions of these efforts have been publishedK~ 
MATERIALS AND METHODS 
Animals and Transplant Procedures 
Female beagle dogs were used for recipients. The donors were 
mongrel dogs. exce~t for groups 2 and 4 in the OlT trials. in 
which a beagle to t-eagle combination was used. Kidney grafts 
were implanted int0 the right iliac fossa and livers implanted were 
into the orthotopl': position using a previously described 
technique .' 
Drug Administration 
FK 506 for intramu>.:ular IJse "as supplied by the Fujlsa\\oa Pharma-
ceutical Co. Ltd. l~KKikaK Japan. This powder was di"ol\ed in saline. 
To pre\'ent yomitirK~ ,;:aused ~I FK 5D6. 2.0 mgkg oi :1tropine sulfate 
was given intmmu;.:ularl, t'-'Ice per day for I \\eek. 
Experimental Designs 
The protocols are ,ummarized In Table I for ren,,! rransplantalilln 
and in qa~le 2 for Jt\'cr transplantation. :\n FK ~lh bolus at a do,e 
of 1.0 mglkgd '-' as gi\en as rescue pulse therapy if rejection 
occurred. FK 506 was never given beyond 90 days after ~urgeryK 
Biochemistry 
Blood samples were taken at 3-day intervals for measurements of 
serum creatinine, total bilirubin. SGOT. SG PT. glucose. and 
amylase. 
Mixed Lymphocyte Reaction 
About 10 ml of l:>lood was drawn every 2 weeks from chronically 
surviving recipients for mixed lymphocyte reaction (MLR) 
studies.· TheIr peripheral lymphocytes were cocultured with 
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Table 1. Prolongation of Renal Allograft Survival in Dogs 
·_··;""""'ilisc .... :a' POStO:-e'2: ,e Days 
"K 506 M~ ~" 3':'6 
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3 10 4.5.6 
4 2.0 4.5.6 
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6 10.0 45.6 
7 50 5 
8 100 5 
9 250 5 
10 05 45. 6 ai~s every 2 weeks 
11 1.0 4.5.6 plt.s every 2 weeks 
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Table 2. Prolongation of Hepatic Allograft Survival In Dogs 
Intramuscular PostOpe'3:-ve Days 
FK 506 of Fo( 506 
Group (mg'kgd) Adm,r'scatlon n 
1 (M.8) 0 c 6 
2 (8/B) 0 C 6 
3 (Mi8) 4.5. 6 7 
4 (BIB) 4.5. 6 8 
• Generalized Wilcoxon test. 
t Dogs died Irom intussusception without Signs of re::-::tlOn 
donor spleen cells or spleen cells of third-party donors, as 
described in a previous report. 4 
Histology 
When animals died or were killed. autopsy '''.is performed imme-
diately. Tissues were fixed with 1O'7c formalin and stained with 
hematoxylin and eosin. 
Statistics 
The Student's 1 test and generalized WilcoxL'n test were applied 
for the statistical analysis of group means. A rr0bability of <0.05 
was considered to be significant. 
RESULTS 
:\5 seen in Tables 1 and 2. significant prolongation of renal 
or hepatic graft survival could be obkined by FK 506 
treatment, \\hen compared with nontreared Jnimals. Two 
OL T dogs survived over 600 Jays after <urgery. and one of 
these IS still alive in good condillon at 1:-:0 postoperative 
days. suggesting tolerance Induction b~ FK 506 delayed 
treatment was achieved. In KT recipient;. there were no 
permanent survivors. in spite of the fact ::-::Jt the rejection-
free period W,,h prolunged. in propurtion [,' Increases in the 
FK ~MS Intramu.,cular dosage IFig I). F,'ur of six dogs 
treated by tntermitknt FK '1)6 admtniD!~ "tiLln Igruup, 10 
and II) suniled for 11~K 127. 12':1. and 1K~O day,. respec-
tile/I. FK ,'On re.,(ue tre:ltment cuul..! -e\er'ie :-:orD~ of 
ongulng re.lectilln epi"lde., In renal .l .. ID~raftI I Fi.[: 21. 
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Fig 1. Re,eclion·lree pe'lod In canine rena ~ otransplantatlon 
treated by dose·dependent. delayed Intramuse a' administration 
of FK 506. 
Survival Time (d) 
7, 8, 19. 26, 41 
7,7,8.13,35,38 
9,t 16,24,28,360, >620,630 
21,126,34,58,60,62,75,193 
Mean P Value' 
18.2 
180 
2410 <0.05 
66.1 <0.01 
unless the serum creallnme levels were higher than 5.0 
mg/dl. As the intramuscular dosage of FK 506 was in-
creased to more than 2.0 mg/kg/d. more of the dogs died 
from intussusception or emaciation. with well-functioning 
kidney grafts (Table I). 
The MLR responses were remarkably suppressed, at 
least for the first month after initial FK 506 delayed 
treatment. in both renal and hepatic recipients. As shown 
in Fig 3. the MLR inhibition of reactivity against donor 
spleen cells at the lIth postoperative week was stronger 
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Fig 2. Outcomes of the FK 506 rescue treatment on the first 
rejection epiSOde In canine renal allograft, 
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Fig 3. Comparison of MLR responses agalrst doror and third· 
party spleen cells at the 11 th postoperative week. The potency of 
responses were evaluated by 3H-thymldlne uptake. 
82 
than that against third-party spleen cells. indicating that 
donor-specific immunosuppression was induced by FK 
506 delayed and intermittent treatment. 
DISCUSSION 
As described in a previous report,1 a 3-day course of 
intramuscular FK 506 at 1.0 mg/kg/d was the best dose for 
optimal graft protection without serious toxic side effects 
in dogs. For both rescue and intermittent FK 506 treat-
ment. even less than 1.0 mg might be sufficient to reverse 
ongoing or recurrent rejection. 
The mechanisms of FK 506-induced long-term allograft 
acceptance have been investigated by Murase et all and 
Ochiai et al. 5 These investigators concluded that there was 
specific immunologic unresponsiveness against the donor 
as a result of delayed treatment in rats with FK 506. 
Although we could not achieve permanent graft accep-
tance after renal allotransplantation in dogs. the MLR 
UEOA. TOOO. EIRAS ET AL 
study showed that antigen recognition was ~pecitlcall:­
reduced by recipient treatment. whether gi'.en transiently 
or repeatedly. Why unresponsiveness was eaSier to induce 
with livers than with kidneys is not presently known. 
it is already known that FK 506-related to\icity is most 
prominent in dogs. ~KS This species peculiarity apparently is 
not relevant to the human situation. 7 
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